Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2014 Dec;14(4):913-8.
doi: 10.4314/ahs.v14i4.20.

Serum HE4 is more suitable as a biomarker than CA125 in Chinese women with benign gynecologic disorders

Yan Zhang  1 , Chunxia Qiao  2 , Lian Li  3 , Xuye Zhao  4 , Yali Li  1
Affiliations

Serum HE4 is more suitable as a biomarker than CA125 in Chinese women with benign gynecologic disorders

Yan Zhang et al. Afr Health Sci. 2014 Dec.

Abstract

Objective: This study measured the human epididymis protein 4 (HE4) and CA125 levels in Chinese women with benign gynecological disorders.

Material and methods: Sera were obtained from Chinese women prior to surgery for a pelvic mass and HE4 and CA125 levels were determined. The proportions of patients with HE4 and CA125 levels were compared.

Results: There were 68 Chinese women with benign diseases. HE4 levels were less elevated than CA125 (1% V.S. 29%, P<0.001). The significant difference was observed in patients with endometriosis/endometriomas in which HE4 was not elevated patients and CA125 was elevated in 53% (P<0.001). Serum HE4 level was not elevated in patients with cystadenoma (0% V.S. 23%, P<0.001) and in patients with germ cell tumors (0% V.S. 5%, P<0.001).

Conclusion: HE4 was less elevated and more suitable as a biomarker than CA125 in chinese women with benign disease.

Keywords: CA125; HE4; benign gynecological disease; biomarker.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Scatte rplot of serum HE4 levels by histopathological classification *Median and 95% percentile were shown in figure 1.
See this image and copyright information in PMC

References

    1. Earle CC, Schrag D, Neville BA, et al. Effect of surgeon specialty on processes of care and outcomes for ovarian cancer patients. J Natl Cancer Inst. 2006;98:172–180. - PubMed
    1. Olaitan A, Weeks J, Mocroft A, et al. The surgical management of women with ovarian cancer in the south west of England. Br J Cancer. 2001;85:1824–1830. - PMC - PubMed
    1. Tingulstad S, Skjeldestad FE, Hagen B. The effect of centralization of primary surgery on survival in ovarian cancer patients. Obstet Gynecol. 2003;102:499–505. - PubMed
    1. Berek JS, Bast RC., Jr Ovarian cancer screening. The use of serial complementary tumor markers to improve sensitivity and specificity for early detection. Cancer. 1995;76:2092–2096. - PubMed
    1. Moore RG, Miller MC, Steinhoff MM, et al. Serum HE4 levels are less frequently elevated than CA125 in women with benign gynecologic disorders. Am J Obstet Gynecol. 2012;206:351.e1–351.e8. - PMC - PubMed

MeSH terms